HighTower Advisors LLC decreased its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 72.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,400 shares of the biopharmaceutical company's stock after selling 387,987 shares during the quarter. HighTower Advisors LLC owned approximately 0.14% of Revance Therapeutics worth $765,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of RVNC. Certuity LLC bought a new stake in shares of Revance Therapeutics in the second quarter worth $26,000. FORA Capital LLC acquired a new position in Revance Therapeutics during the 3rd quarter worth about $54,000. Creative Planning bought a new stake in shares of Revance Therapeutics in the 3rd quarter valued at about $56,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Revance Therapeutics in the second quarter valued at about $33,000. Finally, Accredited Investors Inc. acquired a new stake in shares of Revance Therapeutics in the third quarter valued at about $67,000. Institutional investors own 97.70% of the company's stock.
Revance Therapeutics Price Performance
Shares of RVNC remained flat at $3.07 during trading hours on Thursday. The company had a trading volume of 3,968,710 shares, compared to its average volume of 2,817,201. The stock's 50 day moving average is $4.43 and its 200-day moving average is $4.48. Revance Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $9.74. The firm has a market cap of $322.05 million, a P/E ratio of -1.59 and a beta of 0.81.
Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million for the quarter, compared to analysts' expectations of $67.73 million. Sell-side analysts expect that Revance Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several analysts recently commented on the company. StockNews.com assumed coverage on Revance Therapeutics in a report on Thursday, December 12th. They issued a "hold" rating on the stock. HC Wainwright reaffirmed a "neutral" rating and issued a $6.60 price objective on shares of Revance Therapeutics in a research note on Friday, November 8th. Needham & Company LLC reissued a "hold" rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Mizuho dropped their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a "neutral" rating on the stock in a report on Tuesday, December 10th. Finally, Barclays reiterated an "equal weight" rating and set a $7.00 price target (down from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $8.96.
Check Out Our Latest Analysis on RVNC
Revance Therapeutics Profile
(
Free Report)
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
Featured Stories
Before you consider Revance Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revance Therapeutics wasn't on the list.
While Revance Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.